These pages explain the roles of different health and social professionals, what they do for people with dementia, and how they can help you. If you have been diagnosed with dementia, you are likely ...

Find out what support is available from a GP when a person has dementia, including the role of the GP in dementia care. The GP can support a person even if they don't accept their diagnosis. General ...

This free automatic tax filing service will be offered to “individuals with low or fixed incomes and simple tax situations that remain unchanged from year to year,” Déborah Cléry ...

1:44 FDA approves 1st new type of pain medication in decades U.S. officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with ...

Many of us may struggle with tiredness throughout winter, but extreme fatigue can't always be blamed on the cold and dark weather during November to February. People suffering from low energy and ...

Instead, the pills allow you to stay on track with your daily pill. Birth control pills work by preventing the ovaries from releasing an egg. Normally, an egg leaves an ovary once per month.

Alzheimer’s disease is the most common form of dementia. Anjali Patel, DO, a cognitive neurologist at Atlantic Health System, shares more. Alzheimer’s disease is a progressive neurological disorder ...

The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury, the Associated Press reported. While it provides a long-awaited alternative to ...

Here are six automatic money-saving apps that offer set-it-and-forget-it capabilities. The Acorns micro-investing app puts investing on autopilot thanks to its automatic roundups, which round your ...

An inert and unreactive gas may not seem like an obvious candidate for treating Alzheimer's disease, yet a new study in mice suggests that xenon might just be the breakthrough we need. The new study ...

Vigil Neuroscience (Nasdaq: VIGL) has announced plans to advance its oral TREM2 agonist, VG-3927, into Phase II trials for Alzheimer’s disease this year. The decision follows positive data from a ...

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed ...